Related references
Note: Only part of the references are listed.Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
Grzegorz Helbig et al.
MEDICAL ONCOLOGY (2012)
Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence
Martin M. Crane et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
Animesh Pardanani et al.
BLOOD (2009)
Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2009)
Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations
Florence Roufosse
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome
Grzegorz Helbig et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Pulmonary eosinophilia
Luiz Eduardo Mendes Campos et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2009)
Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy
Princess U. Ogbogu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Mitral Valve Replacement in a Patient with Idiopathic Hypereosinophilic Syndrome and Pulmonary Arterial Hypertension
[Anonymous]
JOURNAL OF CARDIAC SURGERY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib
E. Lierman et al.
LEUKEMIA (2009)
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
Joseph H. Butterfield
LEUKEMIA RESEARCH (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients
Grzegorz Helbig et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review
Maria Ganeva et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2008)
Primary resistance to imatinib in Fip1-like1-platelet-derived growth factor receptor alpha - positive eosinophilic leukemia
Dagmar Simon et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
J. Gotlib et al.
LEUKEMIA (2008)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E. Rothenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia:: implications for optimal dosing
Amy D. Klion et al.
BLOOD (2007)
Eosinophilic gastroenteritis:: A review
Nahum Mendez-Sanchez et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders -: Final result of a phase 2 study
Elias Jabbour et al.
CANCER (2007)
Interferon α induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation
G. Helbig et al.
HAEMATOLOGICA (2007)
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
Michele Baccarani et al.
HAEMATOLOGICA (2007)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
G. Metzgeroth et al.
LEUKEMIA (2007)
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
Jelena V. Jovanovic et al.
BLOOD (2007)
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
Marianna David et al.
BLOOD (2007)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Sorafenib is a potent inhibitor of HP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant
Els Lierman et al.
BLOOD (2006)
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13) (p13;q12) translocation
Ha Vu et al.
LEUKEMIA (2006)
FIP1L1-PDGFRA in eosinophilic disorders:: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature
A. Pardanani et al.
LEUKEMIA RESEARCH (2006)
Allogeneic bone marrow transplantation for hypereosinophilic syndrome:: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript
K. Halaburda et al.
BONE MARROW TRANSPLANTATION (2006)
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)
Nikolas von Bubnoff et al.
BLOOD (2006)
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophihc leukemia (CEL)-like disease
Yoshiyuki Yamada et al.
BLOOD (2006)
Eosinophilia: secondary, clonal and idiopathic
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy
Hiroaki Ohnishi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Idiopathic hypereosinophilic syndrome in children - Report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement
S Rives et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo
EH Stover et al.
BLOOD (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome
E Jabbour et al.
CANCER (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
N von Bubnoff et al.
LEUKEMIA (2005)
Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis
JH Butterfield
ACTA HAEMATOLOGICA (2005)
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophihc syndrome
AD Klion et al.
BLOOD (2004)
The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia:: implications for diagnosis, classification, and management
J Gotlib et al.
BLOOD (2004)
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome
A Sefcick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
AD Klion et al.
BLOOD (2004)
Prevalence, breakpoint distribution, and clinical correlates of t(5;12)
PT Greipp et al.
CANCER GENETICS AND CYTOGENETICS (2004)
Recent advances in pathogenesis and management of hypereosinophilic syndromes
F Roufosse et al.
ALLERGY (2004)
FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
A Pardanani et al.
BLOOD (2004)
Anti-interieukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
JK Garrett et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis
S Plotz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
JH Griffin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
AD Klion et al.
BLOOD (2003)
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
A Pardanani et al.
BLOOD (2003)
Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia
T Matsushima et al.
BLOOD (2003)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
J Cools et al.
CANCER CELL (2003)
The eosinophilias, including the idiopathic hypereosinophilic syndrome
F Brito-Babapulle
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis
S Narayan et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani et al.
BLOOD (2003)
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes
V Pitini et al.
BLOOD (2003)
t(5;9)(q11;q34): A novel familial translocation involving abelson oncogene and association with hypereosinophilia
S Bakhshi et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome
NT Ueno et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
P Ault et al.
LEUKEMIA RESEARCH (2002)
High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome
A de Lavareille et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Treatment of hypereosinophilic syndrome with imatinib mesilate
GJ Gleich et al.
LANCET (2002)
Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome
JH Lee et al.
YONSEI MEDICAL JOURNAL (2002)
Multiple valvar replacements for hypereosinophilic syndrome
DJ Radford et al.
CARDIOLOGY IN THE YOUNG (2002)
Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome
E Juvonen et al.
BONE MARROW TRANSPLANTATION (2002)
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
TK Hart et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes
I Bank et al.
LEUKEMIA & LYMPHOMA (2001)
Clinical and echocardiographic features of hypereosinophilic Syndromes
SR Ommen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome
F Roufosse et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis
L Vazquez et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
